(Bold for FDA approved)
• Induces hyperketonemia and provides an alternative energy substrate to glucose in the brain
• Caprylidene is processed in the gut, resulting in medium-chain fatty acids that pass to the liver and undergo obligate oxidation, ultimately being formed into ketone bodies (acetoacetate and betahydroxybutyric acid)
• Ketone bodies cross the blood–brain barrier and are taken up by neurons and enter the mitochondria, where they increase mitochondrial efficiency
• Ketone bodies also generate ATP and increase pools of acetyl-CoA and acetylcholine
• May begin working immediately
• Diarrhea, flatulence, dyspepsia
• Nausea, headache
• None reported
unusual
unusual
• Take it with food
• Sip it slowly over approximately 30 minutes
• Consider lowering the dose
• 40 g/day
• Powder 40 g/packet
• Not studied
• Drug may lose effectiveness as the course of Alzheimer disease progresses
• No
• Not studied
• Not studied
• Not studied
• Dose adjustment not necessary
• Safety and efficacy have not been established
• Controlled studies have not been conducted in pregnant women
• Animal studies have not shown teratogenic effects
• Unknown if caprylidene is secreted in human breast milk
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera